Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 août 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

NEWARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
09 août 2018 16h01 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on...
02 août 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9

NEWARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
25 juin 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes

NEWARK, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
19 juin 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018

NEWARK, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
08 mai 2018 16h01 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) a clinical-stage biopharmaceutical company focused on...
08 mai 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis

NEWARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
01 mai 2018 08h00 HE | Source: CymaBay Therapeutics, Inc.

CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8

NEWARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
11 avr. 2018 07h47 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018

Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatmentResults from the extended...
15 mars 2018 16h01 HE | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on...

Page précédente